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CASE REPORT
Hyperhomocysteinemia is known to be associ-
ated with an increased risk of arterial and venous
thrombosis.1 The most common genetic defect
that may result in hyperhomocysteinemia is 
a C677T homozygous mutation in the methyl-
enetetrahydrofolate reductase (MTHFR) gene.2
Hyperhomocysteinemia associated with this mu-
tation is more pronounced when low plasma lev-
els of folate, vitamin B6 or vitamin B12 coexist.3
Long-term use of metformin has been shown 
to be able to induce vitamin B12 deficiency.4,5
Herein, we report a metformin-treated diabetic
patient who presented with deep vein throm-
bosis, hyperhomocysteinemia and megaloblas-
tic anemia, which appeared to be related to 
metformin-induced B12 deficiency. The patient
was treated successfully. This report further con-
firms the relationships among hyperhomocys-
teinemia, MTHFR C677T homozygous mutation
and vitamin B12 deficiency, and highlights the
need to test vitamin B12 levels during metformin
treatment.
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Vitamin B12 deficiency may be induced by long-term use of metformin, which may in turn lead to hyper-
homocysteinemia. Thus, hyperhomocysteinemia may increase the risk of vascular thrombosis in diabetic
patients, when metformin is used and a homozygous methylenetetrahydrofolate reductase (MTHFR)
C677T mutation is present. We report a 65-year-old Taiwanese diabetic woman who was treated with met-
formin for 6 years and who had suffered from swelling of the left lower extremity for 3 months. Ascending
venography confirmed the diagnosis of proximal deep vein thrombosis, while hyperhomocysteinemia,
megaloblastic anemia caused by vitamin B12 deficiency, and a homozygous C677T mutation of the
MTHFR gene were also found. She had no identifiable venous thrombotic risk factors other than hyperho-
mocysteinemia, which seemed to be caused by both MTHFR C677T homozygous mutation and vitamin B12
deficiency. With the substitution of insulin injection for metformin, short-term supplement of vitamin B12,
and anticoagulant therapy for the deep vein thrombosis, her anemia and hyperhomocysteinemia recovered
rapidly. The deep vein thrombosis also responded well. Our findings highly suggested the role of met-
formin in causing vitamin B12 deficiency, which may serve as an additional risk factor for venous thrombo-
sis in diabetic patients. Our report also highlights the need to check vitamin B12 levels during metformin
treatment. [J Formos Med Assoc 2007;106(9):774–778]
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Case Report
A 65-year-old Taiwanese woman was admitted
on June 22, 2004 because of swelling of her left
thigh and calf for 3 months, and a pale appear-
ance, generalized weakness and exertional breath-
lessness for 1–2 months. She was found to have
type 2 diabetes mellitus and had been treated
with metformin (500 g twice daily) and gliben-
clamide (10 mg twice daily) since 1998. She had
also suffered from myasthenia gravis associated
with thymoma, which was diagnosed in April
1999 and treated with thymectomy followed by
the use of pyridostigmine bromide. Bilateral pal-
mar numbness sensations were experienced for
several years. She could not recall any remark-
able thromboembolic events in her life or among
her close relatives. She had not received any hor-
mone replacement therapy, nor was any evidence
of malignancy found at admission.
Physical examination revealed nothing abnor-
mal except for a pale face and swelling of the left
lower extremity in addition to the sensation of
numbness in both hands. Her hyperglycemia had
been well controlled, as reflected by her HbA1c
value of 5.8% at admission. Ascending venogra-
phy of her left lower extremity showed an intra-
luminal filling defect at the left popliteal vein and
occlusion of the superficial femoral vein with
multiple collateral circulation at the proximal re-
gion, as well as non-opacification of the left ex-
ternal iliac vein and faint opacification of the left
internal iliac vein (Figure). These findings were
compatible with deep vein thrombosis. The labo-
ratory data before and after admission are shown
in the Table. The main abnormal laboratory find-
ings were an elevated D-dimer value, macrocytic
anemia, an increased level of fasting total homo-
cysteine (measured by fluorescence polarization
immunoassay on an Abbott IMX analyzer), and
a decreased level of vitamin B12 (assayed on an
Abbott AxSYM system based on a microparticle
enzyme immunoassay). No deficiencies in pro-
tein C (114%; normal range, 70–140%), protein S
(81.5%; normal range, 70–123%) or antithrom-
bin III (102.5%; normal range, 70–140%) were
detected. Lupus anticoagulant test was negative,
and the anticardiolipin antibodies (IgG and IgM)
were within normal ranges. Her folic acid level
was normal. The lactate dehydrogenase level was
increased (276 U/L; normal range, 103–193 U/L).
Her haptoglobin level and transferring saturation
were normal. An MTHFR C677T homozygous
gene mutation was detected using the method
described by Frosst et al.2 Bone marrow aspiration
showed notable erythroid megaloblastic change
and giant metamyelocytes, consistent with a di-
agnosis of megaloblastic anemia. Antiparietal cell
antibody was negative. Stomach biopsy showed
no evidence of atrophic gastritis.
Metformin-induced vitamin B12 deficiency
was highly suspected. Therefore, insulin injection
was substituted for metformin to control her hy-
perglycemia. The megaloblastic and macrocytic
anemia was corrected after vitamin B12 supple-
mentation was given. Her hyperhomocysteine-
mia was also rapidly converted to a normal level
(Table). The symptoms and signs of deep vein
thrombosis responded well to anticoagulant ther-
apy. Little improvement was seen in her palmar
Figure. Ascending venography performed on June 22, 2004
shows an intraluminal filling defect in the left popliteal vein,
suggestive of intramural thrombosis, and occlusion of the
superficial femoral vein with multiple collateral circulation at
the proximal region, as well as non-opacification of the left
external iliac vein and faint opacification of the left internal
iliac vein.
H.Y. Lin, et al
776 J Formos Med Assoc | 2007 • Vol 106 • No 9
numbness, which may have resulted from cervical
radiculopathy, as confirmed by magnetic reso-
nance imaging study, rather than from vitamin
B12-deficiency-related neuropathy.
Discussion
Deep vein thrombosis is known to be associated
with many risk factors.6 Acquired contributing
risk factors, such as previous thromboembolic
events, immobilization, recent surgery, malig-
nancy, antiphospholipid antibody, myeloprolif-
erative disorder, and hormone replacement
therapy, were not present in this patient. No defi-
ciencies in protein C, protein S, or antithrombin
III were detected. The two most prevalent heredi-
tary risk factors for venous thrombophilia in
Caucasians, i.e. factor V Leiden and prothrombin
20210A, are extremely rare or even absent in
Taiwanese,7,8 so these two mutations were not
tested for in this patient. The only significant
prothrombotic risk factor identified in our pa-
tient was hyperhomocysteinemia.
Whether or not hyperhomocysteinemia is 
associated with an increased risk of venous throm-
bosis has been investigated and reviewed exten-
sively.9–12 Although our previous study indicated
that hyperhomocysteinemia is possibly not an im-
portant risk factor for venous thrombophilia in
Taiwanese,9 the results of recent meta-analyses sup-
port the notion that hyperhomocysteinemia is an
independent risk factor for venous thrombosis.11,12
The plasma level of total homocysteine is con-
founded by many factors, such as age, sex, nutri-
tion status, smoking, drugs, and diseases.3,9 Our
previous multivariate analysis in healthy subjects
revealed that total plasma homocysteine levels
tended to increase with age (p < 0.001), and with
decreasing plasma levels of folate (p = 0.001) and
vitamin B12 (p < 0.029).9 With the presence of 
a MTHFR C677T homozygous mutation, which
is a common genetic mutation in Taiwanese,13
the total plasma homocysteine level in our 
patient would be elevated to a higher value when
vitamin B12 deficiency is also present. That 
vitamin B12 supplementation rapidly restored
the hyperhomocysteinemia to a normal level
supported the role of vitamin B12 deficiency in
contributing to hyperhomocysteinemia in this
patient.
The vitamin B12 deficiency-induced megalo-
blastic anemia seen in our patient was considered
not to be pernicious anemia, based on the fact that
there was no evidence of atrophic gastritis and
an absence of antiparietal cell antibodies. In fact,
Table. Laboratory findings before and after treatment
Year 2000 2001 2004 2005 2006
Date 09/08 08/03 05/18 06/22* 06/30† 07/05 07/28 08/11 01/07 09/20 08/28
Hematologic findings
WBC (×106/L) 7200 5900 4400 6800 4000 7300 8400 6900 6000 4800 6000
Hb (g/dL) 12.4 11.9 6.9 9.6 8.8 9.1 13.2 12.8 13.4 12.5 13.1
Hct (%) 36.8 36.7 19.4 27.2 26.6 26.9 38.3 38.3 39.7 37.1 38.6
MCV (fL) 87.3 90.1 134 108 110 105 92.1 89.7 84.6 85.2 87.2
Platelets (×109/L) 225 223 110 99 246 359 216 233 221 214 215
Date: 06/26/2004 07/01/2004† 09/20/2005 08/28/2006
Plasma total homocysteine level (µmol/L) 32.04 (< 12)‡ 8.19 5.90 8.31
Date: 06/22/2004 07/01/2004† 09/20/2005 08/28/2006
Plasma vitamin B12 levels (pg/mL) 86.0 (272–1078)‡ > 2000 858.0 577.0
*Packed red blood cells were transfused on May 18; †vitamin B12 injection since June 25, 2004, and no more supplements were given after her discharge on
July 7, 2004; ‡values in parentheses indicate normal ranges. WBC = white blood cell count; Hb = hemoglobin; Hct = hematocrit; MCV = mean corpuscular
volume.
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megaloblastic anemia due to vitamin B12 malab-
sorption associated with long-term metformin
treatment has been previously reported.4,5 It has
been estimated that 10–30% of patients taking
metformin will develop evidence of vitamin B12
deficiency.14 Metformin seems to have an effect
on calcium-dependent membrane action, and the
cobalamine-intrinsic factor complex uptake by
ileal cell surface receptors is known to be calcium-
dependent.15–17 Other proposed mechanisms 
include a bacterial overgrowth in diabetics on
biguanides, leading to increased binding of the
intrinsic factor–vitamin B12 complex to bacteria,
thus decreasing the absorption of vitamin B12.18
Therefore, the vitamin B12 deficiency in this 
patient was very likely to have been induced by
long-term metformin use. After substituting in-
sulin for metformin, her B12 and hemoglobin
levels were still normal 2 years later (Table), even
though no further supplementation of vitamin
B12 was given. These results also support the role
of metformin in causing vitamin B12 deficiency,
and indicate the need to test vitamin B12 levels
during metformin treatment.19
Diabetes mellitus is well known to be associated
with an increased risk for arterial thrombosis.20
It is important to note that hyperhomocysteinemia
may serve as an additional independent risk factor
for vascular thrombosis in diabetic patients when
metformin is used and a MTHFR homozygous
C677T mutation is present.
In conclusion, the deep vein thrombosis in this
diabetic patient was very likely a result of hyper-
homocysteinemia caused by a metformin-induced
vitamin B12 deficiency and a MTHFR C677T ho-
mozygous gene mutation. The successful treat-
ment confirmed this proposition. Our findings
emphasize the need to regularly test vitamin B12
levels during metformin treatment.
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